RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $38.79 million. The enterprise value is $26.61 million.
| Market Cap | 38.79M |
| Enterprise Value | 26.61M |
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 45.10 million shares outstanding. The number of shares has increased by 40.21% in one year.
| Current Share Class | 45.10M |
| Shares Outstanding | 45.10M |
| Shares Change (YoY) | +40.21% |
| Shares Change (QoQ) | +3.75% |
| Owned by Insiders (%) | 3.38% |
| Owned by Institutions (%) | 10.79% |
| Float | 39.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.05 |
| Forward PS | 7.92 |
| PB Ratio | 3.44 |
| P/TBV Ratio | 3.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.15, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.15 |
| Quick Ratio | 6.58 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -100.47% and return on invested capital (ROIC) is -62.12%.
| Return on Equity (ROE) | -100.47% |
| Return on Assets (ROA) | -51.58% |
| Return on Invested Capital (ROIC) | -62.12% |
| Return on Capital Employed (ROCE) | -102.70% |
| Weighted Average Cost of Capital (WACC) | 9.72% |
| Revenue Per Employee | $87,588 |
| Profits Per Employee | -$721,706 |
| Employee Count | 17 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.13% in the last 52 weeks. The beta is 1.00, so RenovoRx's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -38.13% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 45.71 |
| Average Volume (20 Days) | 340,650 |
Short Selling Information
The latest short interest is 384,039, so 0.85% of the outstanding shares have been sold short.
| Short Interest | 384,039 |
| Short Previous Month | 505,892 |
| Short % of Shares Out | 0.85% |
| Short % of Float | 0.96% |
| Short Ratio (days to cover) | 1.34 |
Income Statement
In the last 12 months, RenovoRx had revenue of $1.49 million and -$12.27 million in losses. Loss per share was -$0.33.
| Revenue | 1.49M |
| Gross Profit | 1.17M |
| Operating Income | -12.37M |
| Pretax Income | -12.27M |
| Net Income | -12.27M |
| EBITDA | -12.37M |
| EBIT | -12.37M |
| Loss Per Share | -$0.33 |
Balance Sheet
The company has $12.36 million in cash and $186,000 in debt, with a net cash position of $12.18 million or $0.27 per share.
| Cash & Cash Equivalents | 12.36M |
| Total Debt | 186,000 |
| Net Cash | 12.18M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 11.27M |
| Book Value Per Share | 0.25 |
| Working Capital | 11.80M |
Cash Flow
| Operating Cash Flow | -11.30M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.30M |
| FCF Per Share | -$0.25 |
Margins
| Gross Margin | 78.71% |
| Operating Margin | -830.69% |
| Pretax Margin | -823.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.21% |
| Shareholder Yield | -40.21% |
| Earnings Yield | -31.63% |
| FCF Yield | -29.14% |
Analyst Forecast
The average price target for RenovoRx is $7.03, which is 717.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.03 |
| Price Target Difference | 717.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 224.13% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RenovoRx has an Altman Z-Score of 0.5 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.5 |
| Piotroski F-Score | 3 |